Press and Media

Home / Meetings / Press and Media
Thank you for your coverage of the 麻豆APP Annual Meeting. Please join us at the 2025 麻豆APP Annual Meeting, being held Oct.29-Nov. 1 in San Francisco, California. Journalists covering the annual meeting and posting stories on social media channels are encouraged to use the official meeting hashtag #麻豆APPinSanFran.
Please review the Abstract Embargo Policy. For questions regarding 麻豆APP Annual Meeting policies, please email communications@aanem.org.

View the latest 麻豆APP Achievement Award winners, the , and the latest 麻豆APP news articles on News Express.

Science News: Clinical Trial Finds Telitacicept Reduces MG Symptoms Within Weeks

Jun 26, 2025, 09:59 by Maggie Schmidt (Admin)
Clinical Trial Finds Telitacicept Reduces MG Symptoms Within Weeks
Submitted by: Justin Willer, MD
Edited by: Nakul Katyal, MD

Citation: Yin J, Zhao M, Xu X, et al. A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis. Eur J Neurol. 2024;31(8):e16322. doi:10.1111/ene.16322

Summary: 
Telitacicept is a recombinant Human Beta lymphocyte stimulating factor receptor fusion protein. It comprises the  B-cell stimulating factor receptor(Blys), the extracellular soluble part of the transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and the Fc part of human IgG1. It acts as a dual inhibitor of BlyS and APRIL (a proliferation inducing ligand). This blocks B lymphocyte proliferation and T lymphocyte maturation.

Patients were randomly assigned in a 1:1 ratio to receive either 160 or 240鈥塵g telitacicept subcutaneously once weekly for 24鈥墂eeks in addition to standard-of-care treatment for gMG. The primary efficacy endpoint was the mean change in the quantitative myasthenia gravis (QMG) score from baseline to week 24.  Secondary endpoints included the mean change in the QMG score from baseline to week 12 and the mean change in the MG clinical absolute score from baseline to week 12 and from baseline to week 24. 

Twenty-nine of the 41 patients screened were randomly selected and enrolled. The mean (卤 standard deviation [SD]) reduction in QMG score from baseline to week 24 was 7.7 (卤 5.34) and 9.6 (卤 4.29) in the 160 mg and 240 mg groups, respectively. At week 12, mean reductions in QMG scores for these two groups were 5.8 (卤 5.85) and 9.5(卤 5.03). This indicates rapid improvement.

No statistically significant differences were noted between the two groups in the primary and secondary endpoints. Both groups exhibited a reduction in their QMG score and MG clinical absolute score at week 4 compared to baseline, indicating early clinical improvement in gMG. The reduction in QMG scores were sustained throughout the study period indicating both groups achieved clinical improvement. 

Side effects included decrease in white cell count, upper respiratory infection, diarrhea, injection site reactions, dizziness and UTIs.

Comments:
Telitacicept was well tolerated and reduced the severity of Myasthenia symptoms over the 24 week study period. It had a favorable safety profile.

BAFF is crucial for the survival, differentiation and maturation of B cells whereas APRIL plays a critical role in moderating the function and survival of plasma cells thereby impacting antibody production. Telitacicept combines the extracellular domain of both BAFF and APRIl with the Fc receptor of a human antibody therefore may be more advantageous compared to other B鈥恈ell鈥恡argeted therapies.

Anti CD20 antibodies do not bind to plasma cells and it is thought that part of the limitation of their efficacy is due to lack of CD 20 expression in plasma cells.

Questions? Check out the frequently asked questions below or contact communications@aanem.org. 

Frequently Asked Questions

Q: When will be content of abstracts be viewable, as opposed to just the titles?
A: The abstract content will be available at the annual meeting during the Poster Hall hours. We do not provide abstract presenter information or slides ahead of time. All available information can be found in the 麻豆APP Abstract Guide online when it becomes available.

Q: How do I reach out to abstract or session presenters for an interview?
A: We do not offer member contact information. To connect with abstract or session presenters, review the 麻豆APP Annual Meeting Program when available. Find the topics of interest and connect with the presenter after their lecture or during their abstract poster session time. Currently there is no interview option for virtual attendees.

Q: When can I share information?
A: The embargo on the abstracts themselves is lifted when they have been published in Muscle & Nerve and online in the 麻豆APP Abstract Guide. However, the additional information beyond what is in the abstract itself is still embargoed. 

麻豆APP requires information that goes beyond that which is contained within the abstract, e.g., the release of data not included in the abstract, discussion of the abstract done as part of a scientific presentation, etc. to be embargoed until the start of the annual meeting. Please see the Abstract Embargo Policy.

Q: Will the Abstract Award Reception feature the best posters? 
A: The Abstract Award Reception is a social hour in honor of the abstract award winners where all authors, including award winners, will be available to discuss research. 

Q: Original research is ONLY presented as posters, correct?
A: Yes - the research is presented in the Poster Hall via abstract posters.